New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rukshen Weerasooriya

Prof Rukshen Weerasooriya

ECG Cases with Traces

Dr David Yeo

Dr David Yeo

Gallbladder – When Surgery Is Or Is Not Needed

Dr Susannah Graham & Dr Sanjeev Kumar

Dr Susannah Graham & Dr Sanjeev Kumar

Panel Discussion on Adjuvant Hormone Therapy Post Breast Cancer

Dr Peter Lin

Dr Peter Lin

Covid-19 Infection – What We Know Now

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023